Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for pulmonary arterial hypertension. The company is gaining attention in the market, especially after Amy Li from Jefferies set a price target of $55 for LQDA on January 13, 2026. At that time, the stock was trading at $37.02, suggesting a potential increase of about 48.57%.
Recently, Liquidia's stock price has shown significant movement. The stock experienced a 9.1% increase during a trading session, reaching a high of $34.57 and closing at $34.65. This surge in price was accompanied by a trading volume of approximately 1.89 million shares, which is a 14% increase from the average session volume of 1.67 million shares. The stock had previously closed at $31.76.
The positive sentiment around Liquidia is largely due to its strong commercial performance. The company reported preliminary results indicating robust commercial traction, with estimated net sales for Q4 of YUTREPIA at approximately $90.1 million. For the full year 2025, sales are projected to be around $148.3 million. Additionally, Liquidia reported a positive cash flow exceeding $30 million in Q4 and has approximately $190.7 million in cash on hand.
Liquidia's commercial adoption metrics are also impressive. Since the launch, the company has recorded over 2,800 unique prescriptions and more than 2,200 patients have started treatment. The prescription-to-start conversion rate is approximately 85%, and the expanding prescriber base supports expectations for durable revenue growth. The stock is currently priced at $37.74, reflecting an increase of 3.11% or $1.14, with fluctuations between $35.28 and $38.19 during the trading day.
Over the past year, LQDA has reached a high of $39.16 and a low of $11.26, with a market capitalization of approximately $3.22 billion. Today's trading volume for LQDA is 1,010,747 shares, indicating continued investor interest. Liquidia's strong financial performance and market presence position it well for future growth.
